|
|
|
| home > ebr > Spring 2018 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
EBR Editor Dr Deborah O’Neil looks at the potential of cannabis use in healthcare, relating it to topics discussed in this edition.
|
|
|
|
Future Migraine Treatment
Getting Ahead
Recent advancements in biopharmaceuticals in the area of migraine studies have the potential to bring relief to many individuals. Professor Dr Uwe Reuter at Charité Universitätsmedizin explains how.
|
|
|
|
|
Immunogenicity and the Development of Biopharmaceuticals
Sudden Impact
Dr Gary Bembridge and Dr Karen Hills at Abzena comment on the approaches that can be taken in the pre-clinical stages to reduce the effects of immunogenicity on patient experience and product success.
|
|
|
Technologies for Targeting the Cell Surfaceome
Scratching the Surface
Dr Maria Pavlou and Dr Paul Helbling at Dualsystems Biotech suggest that developing methodologies to study the surfaceome is crucial to cellular differentiation advancement, resulting in the creation of new treatments.
|
|
|
The Potential of Bacterial Lysates
From Pharma to Beauty
Bacterial lysates can be used in many applications, especially disease protection, due to their ability to act as an immune stimulant. Dr Christian Sanchez and Maxence de Villemeur at Lallemand Pharma analyse further.
|
|
|
|
Regulatory Challenges
Rules for Success
Dr William Bridges at Regulatory Affairs Professionals Society believes that regulatory aspects can propel an organisation towards success by enforcing policies, compliance, and good practices.
|
|
|
|
In Brief
Precision Healthcare
EBR’s Industry Advisor, Emile Bellott, surveys the potential ramifications of Amazon’s recently announced healthcare services, which aims to be an affordable solution for consumers.
|
|
|
|
Q&A: Albumin in Cell Culture
Therapy at Work
EBR asked Dr Daniel Shelly at Albumedix about cell therapy, looking specifically at the use of albumin in cell culture and current treatments, as well as the challenges that have to be overcome.
|
|
|
Animal Component-Free Media Formulations
Blood-Free Matters
Dr Randall Alfano at InVitria Product Development describes the use of fetal bovine serum in the advancement of in vitro biology, but suggests that a serum-free media formulation could enhance safety and reproducibility.
|
|
|
Customised Viral Engineering
Proactive Progress
Customised viral engineering can create safe and effective adeno-associated virus gene delivery, reveal Tatjana Buchholz at PlasmidFactory, Dr Carl J Christel at Sirion Biotech, and Dr Hüseyin Besir at PROGEN Biotechnik.
|
|
|
|
|
Capturing Protein-Defining Information
Redefining Proteomics
Mass spectrometry can find the proteins that make a sample, but Dr Christian Loch at AVMBioMed highlights the extract-based functional assay technique.
|
|
|
|
|
Personalised Medicine
At a Glance
Is society ready for personalised medicines and its ethical implications? Guenther Proll at Biametrics has the answer and examines the progress of its sequencing.
|
|
|
Precision Medicine
Beyond the Genome
Dr Jason Mellad at Cambridge Epigenetix states that collaboration is key to realising the potential of epigenetic research, and successive innovations and applications can aid the industry’s understanding of this.
|
|
|
Biomarkers in Oncology
Tomorrow’s Treatments
Tarquin Edwards at Peckwater PR claims that personalising cancer care and using biomarkers and personalised medicine in oncology is being supported by Big Pharma, thus transforming cancer treatments.
|
|
|
|
|
Biobanks and Strategic Processes
Data Swap
Colin Thurston at Brooks Life Sciences recommends adopting three key biobank technology solutions to make research more stratified and effective, thereby aiding researchers.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms.
More info >> |
|
 |
White Papers |
 |
|
Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections
IBT Bioservices
Introduction
Staphylococcus aureus (SA) is a ubiquitous, formidable
Gram-positive pathogen associated with skin and soft tissue, as well as
lifethreatening systemic infections. SA is a leading cause of hospital- and
community-associated infections worldwide, affecting humans and animals. The
wide range of pathologies reflects the diverse abilities of this microbe to
escape the innate and adaptive immune response using virulence factors. Since
its first emergence in the 1960s methicillin-resistant SA (MRSA) has become
endemic in hospitals and healthcare settings worldwide. In the 1990s, community
associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a
major global challenge.
More info >> |
|
 |
Industry Events |
 |
INTERPHEX 2019
2-4 April 2019, Javits Center, New York
At INTERPHEX, find all of the State-of-the-Art Solutions you need to
Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier
pharmaceutical, biotechnology, and medical device development and manufacturing
event and sponsored by Parenteral Drug Association (PDA). Dedicated to
Innovation, Technologies and Knowledge, the show focuses on the entire product
development life cycle.
More info >> |
|
|
